ZOLMITRIPTAN | N021450 | AMNEAL PHARMACEUTICALS LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Impax Laboratories Inc. et al v. Lannett Holdings Inc. et al 2 patentsANDA 206350zolmitriptan | D. Del. | 2014-07-30 | Terminated 2017-04-17 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Alexander Mauskop FDA-2026-P-0925 · 39 docket documents Alexander Mauskop filed this citizen petition in January 2026 requesting that the FDA amend the prescription status of seven triptan medications—sumatriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, almotriptan, and frovatriptan—to allow their availability as over-the-counter products by | Other | 2026-01-30 | Open | Alexander Mauskop |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$108.80
per ea
Lowest NADAC/Unit
$43.41
per ea
Brand NDCs
2
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 64896008412ZOMIG 5 MG NASAL SPRAY | $108.80 | EA | Brand | $43.41 | 2026-06-17 |
| 64896008312ZOMIG 2.5 MG NASAL SPRAY | $108.56 | EA | Brand | — | 2026-02-18 |
| 69238235206ZOLMITRIPTAN 5 MG NASAL SPRAY | $43.41 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.